|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
By Industry | By Industry Segment | By Services and Suppliers
| By Location
| By Hotbed |
Profile Search
|
Esperion Therapeutics, Inc.
3621 S. State Street
695 KMS Place
Ann Arbor
Michigan
48108
U.S.A.
Phone:
734-332-0506
Fax:
734-332-0516
|
Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.
The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.
Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.
Key Management:
Roger Newton, Ph.D.
President and CEO
Timothy Mayleben
Chief Operating Officer and CFO
Last Updated: 01-18-05
Email:
info@esperion.com
Ownership:
Private
Web Site:
Esperion Therapeutics, Inc.
Employees:
Symbol:
|
|
|
Company News |
Esperion Therapeutics, Inc. Files for $70 Million IPO
5/16/2013 7:30:19 AM
More...
|
Esperion Therapeutics, Inc. Presents Full Results of Phase 2 Clinical Trial Showing Its Novel Oral Therapy ETC-1002 Lowered LDL-C By Up to 43 Pct in Hypercholesterolemic Patients With Type 2 Diabetes
5/3/2013 11:04:59 AM
More...
|
Esperion Therapeutics, Inc. Completes $33 Million Preferred Financing
4/25/2013 7:07:45 AM
More...
|
Esperion Therapeutics, Inc. Announces Positive Topline Results from a Phase 2 Clinical Trial of ETC-1002 in Patients with Type 2 Diabetes
1/7/2013 9:58:17 AM
More...
|
Tim Mayleben Named President and CEO of Esperion Therapeutics, Inc.
1/4/2013 7:28:37 AM
More...
|
Esperion Therapeutics, Inc. to Present at 31st Annual J.P. Morgan Healthcare Conference
1/4/2013 6:38:22 AM
More...
|
Noah Rosenberg, MD, Joins Esperion Therapeutics, Inc. as Chief Medical Officer
4/10/2012 8:38:29 AM
More...
|
Esperion Therapeutics, Inc. Announces Positive Phase 2 Clinical Trial Results for ETC-1002
3/26/2012 7:45:36 AM
More...
|
Esperion Therapeutics, Inc. Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
5/2/2011 7:19:55 AM
More...
|
Esperion Therapeutics, Inc. Initiates Phase 2 Clinical Study for ETC-1002
1/6/2011 6:43:19 AM
More...
|
|
|
|
 |
|
|
|
|
|
|
|
|
|